financetom
Business
financetom
/
Business
/
Oracle Results Show Recovery in Key Areas, While Growth Risks Linger, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Oracle Results Show Recovery in Key Areas, While Growth Risks Linger, Morgan Stanley Says
Sep 10, 2024 11:55 PM

11:29 AM EDT, 09/10/2024 (MT Newswires) -- Oracle (ORCL) posted a rebound in bookings growth, strategic applications and cloud infrastructure revenue in fiscal Q1 as "trendlines inflect positively after the Q4 downturn," Morgan Stanley said Tuesday in a report.

Still, gross margins faced pressure and a lag in billings growth indicate risk for the outlook for earnings per share, Morgan Stanley said.

Revenue growth in Q1 was driven by strong license and cloud services figures, the report said.

"The company was able to translate this into earnings per share outperformance as overall gross margins were only down 10 bps in the quarter, while operating expenses continue to decline," Morgan Stanley said.

The firm said concerns linger regarding the durability of growth as an accounting change temporarily supports gross margins, along with reliance on license revenue and subdued capital expenditures.

Morgan Stanley raised its price target on Oracle's stock to $145 from $125 and kept its equalweight rating. At least 20 other analysts boosted their price targets.

On Monday, Oracle reported Q1 adjusted earnings and revenue that topped estimates by analyts. Remaining performance obligations, or future commitments arising from contractual relationships, surged 53% to a record $99 billion, which will bolster revenue growth throughout fiscal 2025, Chief Executive Officer Safra Catz said.

Shares of the company jumped 12% in recent trading Tuesday.

Price: 156.48, Change: +16.59, Percent Change: +11.86

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Flex Opens New Plant to Manufacture Power Products in Dallas
Flex Opens New Plant to Manufacture Power Products in Dallas
Feb 20, 2025
10:34 AM EST, 02/20/2025 (MT Newswires) -- Flex (FLEX) is opening a new 400,000-square-foot manufacturing facility in Dallas to boost production of power products. The plant will increase capacity and efficiency of solutions such as power pods, distribution units and low-voltage switchgear for data centers, Flex said Thursday in a statement. The expansion will help meet the growing demand for...
iQIYI Prices Upsized $350 Million Offering of 2030 Convertible Notes
iQIYI Prices Upsized $350 Million Offering of 2030 Convertible Notes
Feb 20, 2025
10:29 AM EST, 02/20/2025 (MT Newswires) -- iQIYI (IQ) said Thursday it has priced an upsized offering of $350 million of 4.625% convertible senior notes due 2030. The net proceeds of the offering amounted to about $344.8 million, which will be used to repay and/or repurchase debt and for general corporate purposes, the China-based provider of online video services said....
What's Going On With STMicroelectronics Stock Today?
What's Going On With STMicroelectronics Stock Today?
Feb 20, 2025
Shares of semiconductor designing and manufacturing company STMicroelectronics ( STM ) , are trading higher on Thursday. The company is preparing to launch its next-generation technologies aimed at improving optical connections within data centers and AI clusters. As the demand for AI computing grows, issues related to performance and energy efficiency across memory, computing, power supply, and interconnections have surfaced....
Trinity Capital Commits $15 Million in Growth Capital to Cagent Vascular
Trinity Capital Commits $15 Million in Growth Capital to Cagent Vascular
Feb 20, 2025
10:34 AM EST, 02/20/2025 (MT Newswires) -- Trinity Capital ( TRIN ) said Thursday it has committed $15 million in growth capital to medical device company Cagent Vascular. Cagent Vascular is a developer of serration technology that treats peripheral artery disease. The company's flagship product helps improve angioplasty procedures. The funding adds to the $45 million of equity financing led...
Copyright 2023-2026 - www.financetom.com All Rights Reserved